Patients with inoperable metastatic melanoma now have another treatment option as ipilimumab becomes the second immunotherapy drug approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Fortunately for clinicians, ipilimumab also has a new, easier-to-pronounce name–Yervoy. Specifically, Yervoy is indicated for patients with unresectable metastatic melanoma that is newly diagnosed or continues to progress despite prior therapy.
Oral rivaroxaban’s efficacy at reducing the risk of recurrent venous thromboembolism (VTE) was confirmed in two trials presented at the annual meeting of the American Society of Hematology. The agent was studied for treatment of deep-vein thrombosis (DVT) as well as for continued therapy after initial anticoagulation treatment for DVT or pulmonary embolism.
For patients with relapsed or refractory multiple myeloma (MM), bortezomib-based therapy is effective after lenalidomide plus dexamethasone (LD), according to a Canadian study that evaluated sequencing of novel agents presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.